Current Environment:

Summary

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

Conditions

Duchenne Muscular Dystrophy

Recruitment Status

Enrolling by invitation

Eligibility Criteria

Inclusion Criteria:

Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
Is between 7 and 23 years of age, inclusive, at enrollment.

Other inclusion/exclusion criteria apply.

Intervention

Intervention Type

Intervention Name

Drug

Casimersen

Drug

Golodirsen

Phase

Phase 3

Gender

Male

Min Age

7 Years

Max Age

23 Years

Download Date

August 5, 2022

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team: